Board Change • May 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • May 01
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Shannon Robinson was the last director to join the board, commencing their role in 2025. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Feb 04
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.262595 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Anuncio • Jan 07
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 0.335776 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 27,981,343
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Rights Offering Board Change • Dec 31
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Anuncio • Dec 17
Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million. Pathkey.AI Ltd has filed a Follow-on Equity Offering in the amount of AUD 2.262595 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Anuncio • Nov 27
Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million. Pathkey.AI Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 19,783,786
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 188,549,547
Price\Range: AUD 0.012
Discount Per Security: AUD 0.00072
Transaction Features: Subsequent Direct Listing Anuncio • Oct 02
Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025 Pathkey.AI Ltd, Annual General Meeting, Nov 26, 2025. New Risk • Aug 31
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -AU$1.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$1.3m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Negative equity (-AU$268k). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (73% increase in shares outstanding). Revenue is less than US$1m (AU$322k revenue, or US$211k). Market cap is less than US$10m (AU$7.10m market cap, or US$4.65m). Reported Earnings • Aug 31
Full year 2025 earnings released: AU$0.008 loss per share (vs AU$0.018 loss in FY 2024) Full year 2025 results: AU$0.008 loss per share (improved from AU$0.018 loss in FY 2024). Net loss: AU$1.45m (loss narrowed 54% from FY 2024). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Board Change • Aug 18
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 5 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Anuncio • May 02
Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million. Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 1.5 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 42,000,000
Price\Range: AUD 0.021
Discount Per Security: AUD 0.00126
Security Features: Attached Options
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 29,428,572
Price\Range: AUD 0.021
Discount Per Security: AUD 0.00126
Security Features: Attached Options
Transaction Features: Subsequent Direct Listing Anuncio • Oct 11
Opyl Limited, Annual General Meeting, Nov 21, 2024 Opyl Limited, Annual General Meeting, Nov 21, 2024. Anuncio • Sep 05
Opyl Limited Announces Company Secretary Changes Opyl Limited announced the appointment of Mr. Jonathan Hart as the new Company Secretary, effective immediately. Mr. Hart has 20+ years of corporate advisory experience. He has extensive cross border experience specializing in corporate advisory, scale up and debt and equity financing, across a broad range of industry sectors. Mr. Hart holds a Bachelor of Laws and Commerce and currently serves as a director of Hartness Consulting Pty Ltd, established in 2012 specializing in corporate advisory and equity services to private and publicly listed companies in a range of sectors including technology, healthcare and resources. His extensive experience and deep understanding of corporate governance, compliance, and
strategic advisory will be instrumental as Opyl continues to execute its strategic initiatives. The Board takes this opportunity to thank Mr. David Lilja of DLK Advisory for his invaluable
contributions to the Company as the outgoing Company Secretary. Reported Earnings • Aug 31
Full year 2024 earnings released: AU$0.018 loss per share (vs AU$0.022 loss in FY 2023) Full year 2024 results: AU$0.018 loss per share. Revenue: AU$932.1k (up 51% from FY 2023). Net loss: AU$3.13m (loss widened 81% from FY 2023). Anuncio • Aug 23
Opyl Limited announced that it has received AUD 0.7 million in funding Opyl Limited announced that it has received AUD 700,000 through short-term loan agreements in funding on August 22, 2024. The transaction includes participation from new lenders Peak Asset Management LLC, Irwin Biotech Nominees Pty Ltd, Rip Opportunities Pty Ltd and Antanas "Tony" Guoga. Anuncio • Apr 30
Opyl Limited, Annual General Meeting, May 27, 2024 Opyl Limited, Annual General Meeting, May 27, 2024, at 15:00 E. Australia Standard Time. Agenda: To consider approval of disposal of OPIN business; to election of executive-director Mr. Saurabh Jain; to approval of issue of shares to Mr. Mark Ziirsen conversion of director fees outstanding; to approval of issue of shares to Mr. Damon Rasheed conversion of director fees outstanding; to approval of issue of shares to Mr. Antanas Guoga conversion of director fees outstanding; to approval to issue of 10,000,000 lead manager options; to ratification of prior issue of 19,200,000 placement shares; to ratification of prior issue of 429,185 shares; and to consider other matters if any. Board Change • Mar 20
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Feb 06
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Jan 17
Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million. Opyl Limited has completed a Follow-on Equity Offering in the amount of AUD 0.687158 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 22,905,260
Price\Range: AUD 0.03
Discount Per Security: AUD 0.0018
Transaction Features: Rights Offering Board Change • Jan 12
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Nov 24
Opyl Limited Appoints Saurabh Jain as Interim Chief Executive Officer Opyl Limited announced the appointment of Mr. Saurabh Jain as interim Chief Executive Officer of Opyl, effective 24 November 2023. Saurabh is tasked with overseeing and driving the launch of Opyl's new predictive analytics and insights platform, TrialKey, and continuing to support the Opin business as it executes on its new go-to-market strategy. Saurabh is an accomplished technology entrepreneur with a track record of commercialising, scaling and transitioning management to proven leadership in emerging technology businesses. In 1997, he founded Netpro Express, an internet service provider that was later acquired by Telstra. Since then, Saurabh has held various senior executive roles at Ventia, Cushman Wakefield and was previously CEO and Executive Director of Urbanise. Most recently, Saurabh joined the Spacetalk board where he stepped into the role of acting CEO before transitioning to the current leadership, at which point he stepped back into his prior role as Non-Executive Director. Saurabh brings over 25 years of experience across both ASX boards and private companies, leveraging his entrepreneurial and commercial acumen, a history of deep technical expertise and oversight over transformative organisational change. His experience will be critical in accelerating the commercialisation of TrialKey, overseeing the growth of Opin, and driving equity value uplift across the business. Saurabh holds a Bachelor of Engineering (Software Engineering), an Executive Master of Business Administration and a Master of Business Technology from the Australian Graduate School of Management, UNSW. Board Change • Nov 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Non-Executive Director Mark Simari was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Anuncio • Oct 31
Opyl Limited, Annual General Meeting, Nov 29, 2023 Opyl Limited, Annual General Meeting, Nov 29, 2023, at 15:00 AUS Eastern Standard Time. Location: Engine House, 105 Wellington Street Saint Kilda Victoria Australia Agenda: To receive the Financial Statements, Director's Report and Auditor's Report for the Company for the year ended 30 June 2023; to consider and approve the remuneration report; to consider and approve the election of Director; to consider and approve to issue of incentive options; to consider and approve the conversion of Director fees; to consider and approve to issue loan options; and to consider and approve the 10% placement capacity. New Risk • Jul 10
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 61% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$886k free cash flow). Shares are highly illiquid. Shareholders have been substantially diluted in the past year (61% increase in shares outstanding). Revenue is less than US$1m (AU$901k revenue, or US$603k). Market cap is less than US$10m (AU$3.66m market cap, or US$2.45m). Board Change • Jun 28
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Board Change • Jun 05
No independent directors There are 3 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 3 new directors. 6 experienced directors. No highly experienced directors. No independent directors (3 non-independent directors). Member of Advisory Board Kirsten Daru is the most experienced director on the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors. Anuncio • May 04
Opyl Limited Appoints Dr. Hugo Stephenson as Board Advisor Opyl Limited announced that it has engaged leading global clinical trial expert and eminent business leader in the health technology sector, Dr. Hugo Stephenson, as an advisor to the board. His appointment is an important development in the Company's strategic review, which focuses on accelerating the growth of Opin and monetising the TrialKey technology platform. Dr. Stephenson is a medical doctor, technologist, biotech services entrepreneur and founder of a number of successful businesses in the international clinical trials industry, including: DrugDev, a leading provider of e-clinical technologies and clinical trial payment services; MediGuard, the largest online medication monitoring service; Health Research Solutions (HRS), a late phase contract research organisation; and MedSeed, a pioneer of hospital and GP decision support software. Dr. Stephenson worked for many years as the founder of Quintiles' global late phase research division (now IQVIA) following the acquisition of HRS, and has considerable experience managing organisations within both a public market and private equity-backed environment. He is also the founder and past Chief Executive Officer of the Induction Healthcare Group PLC. Board Change • May 02
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Megan Robertson was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.